Jiten Vora
Jiten Vora
Verified email at
Cited by
Cited by
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised …
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with ...
The Lancet 372 (9644), 1174-1183, 2008
Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle‐aged men compared with those in young men
MJ Diver, KE Imtiaz, AM Ahmad, JP Vora, WD Fraser
Clinical endocrinology 58 (6), 710-717, 2003
Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study
SP Harding, DM Broadbent, C Neoh, MC White, J Vora
Bmj 311 (7013), 1131-1135, 1995
Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study
N Younis, DM Broadbent, JP Vora, SP Harding
The Lancet 361 (9353), 195-200, 2003
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
AH Barnett, P Mackin, I Chaudhry, A Farooqi, R Gadsby, A Heald, J Hill, ...
Journal of Psychopharmacology 21 (4), 357-373, 2007
Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus
JP Vora, J Dolben, JD Dean, D Thomas, JD Williams, DR Owens, ...
Kidney international 41 (4), 829-835, 1992
Cost effectiveness analysis of screening for sight threatening diabetic eye disease
M James, DA Turner, DM Broadbent, J Vora, SP Harding
Bmj 320 (7250), 1627-1631, 2000
A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
M Evans, PM Schumm‐Draeger, J Vora, AB King
Diabetes, Obesity and Metabolism 13 (8), 677-684, 2011
Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial
PKC-DMES study group
Archives of ophthalmology (Chicago, Ill.: 1960) 125 (3), 318-324, 2007
Cutaneous manifestations of the malignant carcinoid syndrome
HK Bell, GJ Poston, J Vora, NJE Wilson
British Journal of dermatology 152 (1), 71-75, 2005
Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice
K Khunti, T Damci, L Meneghini, CY Pan, JF Yale, SOLVE Study Group
Diabetes, Obesity and Metabolism 14 (7), 654-661, 2012
Incidence of sight‐threatening retinopathy in Type 1 diabetes in a systematic screening programme
N Younis, DM Broadbent, SP Harding, JP Vora
Diabetic Medicine 20 (9), 758-765, 2003
Long-term effects of insulin glargine on the risk of breast cancer
S Suissa, L Azoulay, S Dell’Aniello, M Evans, J Vora, M Pollak
Diabetologia 54, 2254-2262, 2011
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: AB ayesian meta‐analysis of survival data
S Bain, E Druyts, C Balijepalli, CA Baxter, CJ Currie, R Das, R Donnelly, ...
Diabetes, Obesity and Metabolism 19 (3), 329-335, 2017
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 …
L Niskanen, LE Jensen, J Råstam, L Nygaard-Pedersen, K Erichsen, ...
Clinical therapeutics 26 (4), 531-540, 2004
Surgery for midgut carcinoid.
R Sutton, HE Doran, EMI Williams, J Vora, S Vinjamuri, J Evans, ...
Endocrine-Related Cancer 10 (4), 469-481, 2003
Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry
JP Vora, A Burch, JR Peters, DR Owens
Diabetes Care 15 (11), 1484-1493, 1992
Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective study
TMCS Group
Diabetic Medicine 16 (11), 918-925, 1999
Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome
G Leese, P Chattington, W Fraser, J Vora, R Edwards, G Williams
The Journal of Clinical Endocrinology & Metabolism 81 (5), 1867-1870, 1996
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials
J Vora, T Christensen, A Rana, SC Bain
Diabetes therapy 5, 435-446, 2014
The system can't perform the operation now. Try again later.
Articles 1–20